MaxCyte Q1 2025 revenue down 8% to $10.4M; reiterates FY2025 guidance

MAXCYTE, INC.

2026-Q1 EPS reported -$0.10 vs consensus -$0.08 ▼ miss (-22.5%)

Total revenue $10.4M (-8% YoY); core revenue $8.2M (+1%); SPL program revenue $2.1M (-32%).
Net loss $10.3M vs $9.5M in Q1 2024; cash $174.7M as of March 31, 2025.
Added one SPL client (TG Therapeutics); total active SPLs now 29.
Reiterates FY2025: core revenue growth 8-15%, SPL program revenue ~$5M, ending cash ~$160M.
Integration of SeQure Dx ongoing; management cites robust SPL pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.